Date: 2014-12-18
Type of information: Fundraising
Company: Ecrins Therapeutics (France)
Investors: WiSEED (France)
Amount:
Funding type: fundraising
Planned used: Founded in 2010, Ecrins Therapeutics develops ET-D5. This drug candidate was discovered in the course of the research program run by a team of biologists (and future co-founders of Ecrins Therapeutics) at INSERM, University of Grenoble and Institut Curie. ET-D5 is a cytostatic and anti-vascular agent. In this way, ET-D5 deprives the tumor of needed oxygen and nutrients and eventually causes cancer cells to die. Importantly, ET-D5 has an original molecular target and it can be administered orally. The first clinical trial has been already scheduled to begin in 2016 at the Léon Berard Cancer Center (Lyon, France).
The fundraising campaign will allow Ecrins Therapeutics to clear the final regulatory hurdle, leading to the clinical trial authorization.
Others: * On December 18, 2014, Ecrins Therapeutics, a Fench-based cancer-fighting startup, has begun the fundraising process on the French crowdfunding platform Wiseed. The company aims to raise 500 000€ via Wiseed.
Therapeutic area: Cancer - Oncology
